Deep Vein Thrombosis (DVT) News and Research

RSS

Ultrasound strategy excludes DVT in pregnant women

Serial compression ultrasonography with iliac vein visualization can reliably exclude deep vein thrombosis in symptomatic pregnant women, according to results from an 8-year prospective cohort study published in the Canadian Medical Association Journal.

22 Jan 2013

Selective strategy for D-dimer testing in DVT

Selecting certain patients for D-dimer testing appears to be a safe and more efficient way of diagnosing deep vein thrombosis than uniformly testing all patients suspected of having the condition, report researchers.

16 Jan 2013

Link between infections and venous thromboembolism in surgical patients

Despite receiving blood thinners and other clot prevention treatment, some patients still develop potentially lethal blood clots in the first month after their operations anyway, especially if they developed a surgical-site infection while in the hospital, according to results of a study at Johns Hopkins.

16 Jan 2013

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Arthritis translates to “joint inflammation.” The most common form of arthritis is osteoarthritis (OA), which affects 12-15% of North Americans over the age of 60, and will increase in prevalence as our population ages.

19 Dec 2012

Studies examine current treatment standards for patients with clotting disorders

Studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes.

11 Dec 2012

Algorithms improve certainty in ruling out deep and pelvic vein thrombosis at primary level of patient care

Algorithms improve certainty in ruling out deep and pelvic vein thrombosis at the primary level of patient care, say Lobna El Tabei and her co-authors in the current issue of the Deutsches Ärzteblatt International.

27 Nov 2012

FDA expands Janssen’s Xarelto use to reduce risk of DVT and PE

The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.

3 Nov 2012

Premier, ArjoHuntleigh announce three-year contract for vascular compression therapy systems

ArjoHuntleigh announced today that it has been awarded a three-year contract with Premier Purchasing Partners, L.P., the group purchasing unit of the Premier healthcare alliance, for its vascular compression therapy systems.

4 Oct 2012

Low blood anticoagulant levels increase risk for VTE

Low plasma levels of antithrombin, protein C, and protein S significantly increase the risk for venous thromboembolism, Italian research shows.

25 Jul 2012

Knee surgery blood loss reduced with single tranexamic acid dose

A single intraoperative dose of tranexamic acid is effective at reducing blood loss in patients undergoing minimally invasive total knee arthroplasty, research suggests.

20 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

ThromboGenics NV and co-development partner BioInvent International announce today the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban, an oral anticoagulant.

5 Jun 2012

Orthopaedic research studies in the Journal of Bone and Joint Surgery

Below are highlights of orthopaedic research studies appearing in the April 18th issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issue's full Table of Contents.

21 Apr 2012

Rivaroxaban found safe and effective in pulmonary embolism

Rivaroxaban has been found to be effective in the prevention of venous thromboembolism (VTE) after orthopedic surgery, for the prevention of stroke in AF (Atrial fibrillation) patients, and as additional therapy to conventional antiplatelet therapy in ACS (Acute coronary syndrome) patients.

27 Mar 2012

Minimally invasive treatments re-establish blood flow in people with chronic DVT

Interventional radiology treatments re-establish blood flow in people with chronic deep vein thrombosis (DVT), reducing disabling symptoms and improving the quality of life for those afflicted with post-thrombotic syndrome—an under-recognized but frequent long-term complication of DVT.

27 Mar 2012

Rivaroxaban safer, effective than standard therapy in treating PE

A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism - a blockage of lung blood vessels usually caused by a clot - and showed comparable efficacy, according to data from the EINSTEIN-PE trial presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

Thromboembolic events can occur after musculoskeletal injury and related surgery

Below is a news summary of an orthopaedic research study appearing in the March 21, 2012 issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issues' full Table of Contents.

22 Mar 2012

Westmead Hospital endorse a new medical device designed to increase blood circulation and prevent Deep Vein Thrombosis

A new medical device, the geko™, designed to increase blood circulation through neuromuscular electro–stimulation to the common peroneal nerve, has received the positive endorsement of Westmead Hospital, New South Wales, as an important new development in the prevention of Deep Vein Thrombosis (DVT).

18 Mar 2012

Anticoagulation drugs can prevent PE, DVT after total joint replacement

Following a total joint replacement, anticoagulation (blood thinning) drugs can prevent Deep Vein Thrombosis (DVT), a blood clot deep within the extremities, or a pulmonary embolism (PE), a complication that causes a blood clot to move to the lungs.

7 Feb 2012

New ACCP guidelines address DVT/PE risk factors for long-distance travel

New evidence-based guidelines from the American College of Chest Physicians (ACCP) address the many risk factors for developing a deep vein thrombosis (DVT), or blood clot, as the result of long-distance travel.

7 Feb 2012

Deep Vein Thrombosis (DVT) News and Research

Ultrasound strategy excludes DVT in pregnant women

Selective strategy for D-dimer testing in DVT

Link between infections and venous thromboembolism in surgical patients

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Studies examine current treatment standards for patients with clotting disorders

Algorithms improve certainty in ruling out deep and pelvic vein thrombosis at primary level of patient care

FDA expands Janssen’s Xarelto use to reduce risk of DVT and PE

Premier, ArjoHuntleigh announce three-year contract for vascular compression therapy systems

Low blood anticoagulant levels increase risk for VTE

Knee surgery blood loss reduced with single tranexamic acid dose

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

Orthopaedic research studies in the Journal of Bone and Joint Surgery

Rivaroxaban found safe and effective in pulmonary embolism

Minimally invasive treatments re-establish blood flow in people with chronic DVT

Rivaroxaban safer, effective than standard therapy in treating PE

Thromboembolic events can occur after musculoskeletal injury and related surgery

Westmead Hospital endorse a new medical device designed to increase blood circulation and prevent Deep Vein Thrombosis

Anticoagulation drugs can prevent PE, DVT after total joint replacement

New ACCP guidelines address DVT/PE risk factors for long-distance travel

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News